The number of deaths linked to diabetes and weight loss drugs in the UK has risen to 82, according to new data from the country’s medicines regulator.
The Medicines and Healthcare Products Regulatory Agency (MHRA) released the latest figures on GLP-1 receptor agonist drugs such as Mounjaro, Wegovy, and Ozempic, up to January 31. These drugs have been increasingly used for weight loss, contributing to a rise in reported deaths.
Out of the 82 deaths, 22 were attributed to the use of these drugs for weight loss, a significant rise from 10 in October. The figures come from medical reports that document adverse reactions to medicines. However, the MHRA noted that the deaths may not necessarily have been caused by the drugs alone, as underlying health conditions could have also played a role.
As of January, the MHRA had received reports of 18 deaths linked to Mounjaro (tirzepatide), 29 deaths related to Ozempic, Rybelsus, and Wegovy (semaglutide), and 35 deaths associated with Saxenda or Victoza (liraglutide).
The drugs have become widely popular, leading regulators to focus on ensuring proper prescribing. The pharmacy watchdog has tightened guidelines on how these drugs are dispensed, while the advertising regulator is investigating nine cases of alleged improper marketing.
In response to the rising death toll, NHS medical director Professor Sir Stephen Powis emphasized that weight loss drugs have potential side effects. He stressed the importance of having these drugs prescribed by trained healthcare professionals and not purchased online. He also pointed out that these medications are not a “magic bullet” and should be used in conjunction with healthy lifestyle changes, including improved diet and physical activity.
GLP-1 receptor agonists have been used to treat type 2 diabetes for over 15 years, but their use for weight loss began to increase around seven years ago.
Mounjaro manufacturer Eli Lilly issued a statement saying that patient safety is its top priority. The company stated that it actively monitors and reports safety data, noting that tirzepatide is approved for both type 2 diabetes treatment and weight management.
Novo Nordisk, the maker of Ozempic, Rybelsus, and Wegovy, also emphasized the importance of using these drugs for their approved purposes under professional supervision. The company assured the public that it continuously monitors safety data and works closely with authorities to ensure patient safety.
